3 Big Stories in Gilead Sciences' Q1 Results
It's unusual for Gilead Sciences' (NASDAQ: GILD) quarterly update to be the third-biggest story for the company. But that's exactly what happened this week.
Gilead announced its first-quarter results after the market closed on Thursday. However, the day before, the biotech reported encouraging results from the first of two late-stage studies evaluating remdesivir in treating novel coronavirus disease COVID-19. Also on Wednesday, the National Institute of Allergy and Infectious Diseases (NIAID) released positive data from another late-stage study of remdesivir.
The two simultaneous updates for Gilead's antiviral drug kind of overshadowed the company's Q1 results. Don't overlook the biotech's Q1 numbers, though. Here are three big stories in Gilead's Q1 update that you'll really want to know about.
Source Fool.com
